Orchestra BioMed (OBIO) Insider Ann Buys 17,327 Shares

Pamela Ann Connealy recently purchased 17,327 shares of OBIO as part of insider trading activity on June 23, 2026. This transaction did not involve a pre-planned trading arrangement, which suggests a direct investment decision by Connealy.

Insider Buying and Selling at Orchestra BioMed Holdings, Inc.

Alongside Connealy's purchase, other insiders were active in trading OBIO shares. On June 23, 2026, Jason Aryeh also bought 42,553 shares, while Eric Fain acquired 17,327 shares. The following day, June 24, 2026, insiders including Chris Cleary, John Prosper Mack, Eric Fain, and David Pacitti sold shares, ranging from 3,510 to 4,261 shares each.

Other Institutional Activity in OBIO

In recent institutional trading, RTW Investments, LP held steady with 8,306,063 shares valued at approximately $35.3 million. Perceptive Advisors LLC slightly reduced its stake by 89,350 shares, now holding 5,037,906 shares worth about $21.4 million, a 1.7% decrease. Vanguard Capital Management LLC opened a new position with 2,204,319 shares valued at roughly $9.4 million. Propel Bio Management, LLC also initiated a new stake with 896,701 shares, valued at about $3.8 million. Millennium Management LLC notably increased its position by 459,070 shares, now holding 702,543 shares valued at approximately $3 million, marking a 188.6% increase.

Orchestra BioMed Holdings, Inc. Stock Down 34.5%

Shares of OBIO traded at $3.98 on Friday. The company has been the focus of various institutional and insider activities, reflecting its ongoing market interest.

Analysts Set New Price Targets

Several analysts have maintained a positive outlook on OBIO. On May 19, 2026, B. Riley Securities maintained a 'buy' rating with a $10.0 price target. HC Wainwright & Co. reiterated their 'buy' rating on May 14, 2026, also targeting $10.0. Barclays maintained its 'buy' rating with a $13.0 target on May 13, 2026. Chardan Capital has been consistent in its 'buy' rating, with a high target of $20.0 set on March 12, 2026. Overall, OBIO has a consensus 'buy' recommendation among analysts.

Bottom Line

Pamela Ann Connealy's purchase of OBIO shares highlights the insider interest in the company. With institutional investors like Millennium Management significantly increasing their holdings, OBIO continues to attract attention. Analysts' consistent 'buy' ratings further underscore the market's positive sentiment, although investors should remember that insider trades are disclosed after the fact and may not reflect current positions.